Drug intelligence / Profile preview

Piwei Peiyuan granules

Development stage: Unknown
Lead developer: Second Affiliated Hospital of Anhui University of Traditional Chinese Medicine
Administration: Oral

Overview

Piwei Peiyuan granules is a Traditional Chinese Medicine (TCM) formulation developed by the Second Affiliated Hospital of Anhui University of Traditional Chinese Medicine. It is primarily indicated for the treatment of chronic atrophic gastritis (CAG), specifically targeting the spleen-stomach weakness syndrome. The formulation is intended to strengthen the spleen, replenish original qi, and promote the repair of the gastric mucosa. It has been studied in a multi-center, randomized, double-blind, phase 0 clinical trial in China, where it was compared against Weifuchun tablets to evaluate its clinical efficacy and safety.

Other names: Piwei Peiyuan recipePiwei Peiyuan formula

Beyond the preview

Go deeper on Piwei Peiyuan granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Piwei Peiyuan granules.

Explore the full profile